Psoriasis and immunity: evidence from skin grafts and human cells
Psoriasis and immunity became inseparable subjects as experiments traced the scaly skin condition to interactions among immune cells and the body's own tissues. Psoriasis is noncommunicable: ordinary skin contact does not transfer it between people. The World Health Organization placed that classification at the center of its 2016 global report. Laboratory research supplies a different kind of evidence, showing how particular immune cells can participate in producing lesions. Together, the institutional record and the experimental record describe a disease whose visible surface changes have sometimes brought social exclusion as well as physical discomfort.
The visible plaques are only one part of that biological picture. DermNet classifies psoriasis as an immune-mediated genetic skin disease involving both innate and adaptive immunity. Its clinical descriptions include sharply defined, scaly plaques, commonly on the scalp, elbows and knees, and changes in the nails. The same reference describes considerable variation in color: thick plaques can appear violet or dark on darker skin, while early pinkness can be difficult to recognize. It also identifies a genetic association between HLA-C*06:02 and early-onset or guttate psoriasis, distinguishing that association from late-onset disease and nail or joint involvement. The finding concerns inherited susceptibility and disease patterns. The characteristic scale therefore belongs to an inflammatory process that can have different appearances across skin types, rather than a single uniform mark.
A particularly revealing experiment appeared in the American Journal of Pathology in 1999. Brian Nickoloff and Tamara Wrone-Smith studied symptomless skin from people with psoriasis after that tissue had been grafted onto mice with severe immune deficiencies. They compared immune-cell populations obtained from the same human donors. In material from five patients, CD4 T-cell lines induced psoriatic lesions; the CD8 lines tested did not. This was a controlled experimental model involving human tissue and donor-matched immune cells, rather than an observation that people sharing a room developed similar skin changes.
The resulting tissue also showed a more complicated response than simple arrival of the injected cells. In some grafts, CD8 cells already present in the skin became activated and increased in number after the CD4 cells were introduced. Microscopic staining identified activation markers and changes in the epidermis associated with psoriasis. The findings linked several cell populations in a local inflammatory sequence. They also had clear boundaries: the work involved selected tissues in a mouse model, and the behavior of one isolated cell population in that setting did not establish its role in every person with psoriasis.
Research on psoriasis and immunity later identified a specific target for some of those immune responses. In a 2014 Nature Communications study, Roberto Lande and colleagues investigated LL37, an antimicrobial peptide present in unusually large amounts in psoriatic skin. They found T cells recognizing LL37 in about two-thirds of the patients with moderate-to-severe plaque psoriasis whom they studied. Both CD4 and CD8 responses occurred. That observation gave the autoimmune description a concrete molecular connection: immune cells were responding to a substance produced within the body, rather than simply appearing near inflamed tissue.
The LL37 findings connected blood measurements with the skin itself. The investigators identified LL37-specific cells capable of entering lesions and reported a relationship between circulating responses and disease activity. The responding cells released inflammatory signaling molecules, including interferon gamma; CD4 cells also produced cytokines associated with the Th17 response. The authors presented LL37 as a T-cell autoantigen and evidence for participation of antimicrobial peptides in immune activation. Their findings concerned a particular response within the studied population. They did not identify one universal initiating event or suggest that every patient had the same measurable immune target.
Institutional recognition followed a separate evidential route. WHO's announcement of the report on 26 February 2016 recalled the World Health Assembly's 2014 resolution on awareness and stigma. The announcement called for more research into psoriasis and stronger professional training, alongside action against discrimination. These were public health priorities addressing recognition and access. They concerned the organization of services and people's place in society, while the cell experiments investigated local immune activity. The report's policy recommendations therefore added a social and institutional record to the laboratory findings.
WHO's 2016 publication described exclusion, loneliness, lost professional opportunities and financial burdens among people with psoriasis. It also recognized involvement of nails and joints, including chronic inflammatory arthritis in some patients. The report widened the institutional picture beyond the area of skin visibly affected. Psoriasis and immunity had acquired increasingly specific experimental evidence, while the global report documented consequences that cell assays could not measure: disability, isolation and the cost of living with a persistent condition. Those two developments concerned different scales of the same disease, from immune recognition inside tissue to participation in social and working life.
- World Health Organization, Global report on psoriasis, 2016 — www.who.int
- Nickoloff and Wrone-Smith, Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis, 1999 — pmc.ncbi.nlm.nih.gov
- Lande and colleagues, The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis, 2014 — www.nature.com
- World Health Organization, WHO publishes new report on psoriasis, 26 February 2016 — www.who.int
- DermNet, Psoriasis: clinical features and immune-mediated classification — dermnetnz.org